It should be noted that the CD133 receptor, usually detected with the AC133 epitope monoclonal antibody, can become truncated, thereby hindering the antibody’s access to its binding region and leading to false-negative CD133 expression results in cancer cell populations [96]. This evidence concerns the gene PROM1 and cancer.